Moderna, Inc. (NASDAQ:MRNA)’s share price traded down 9% on Monday after an insider sold shares in the company. The company traded as low as $138.18 and last traded at $145.60. 573,564 shares changed hands during trading, a decline of 94% from the average session volume of 9,188,346 shares. The stock had previously closed at $160.07.Specifically, insider Juan Andres sold 5,000 shares of the business’s stock in a transaction on Monday, November 29th. The stock was sold at an average price of $370.38, for a total value of $1,851,900.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephane Bancel sold 9,000 shares of the business’s stock in a transaction on Wednesday, January 19th. The stock was sold at an average price of $188.55, for a total value of $1,696,950.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 369,000 shares of company stock worth $100,291,780. 19.40% of the stock is owned by company insiders.
MRNA has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Moderna in a research note on Friday, October 22nd. They issued a “sell” rating and a $250.00 target price for the company. SVB Leerink reiterated a “sell” rating on shares of Moderna in a research note on Thursday, December 23rd. The Goldman Sachs Group reiterated a “buy” rating and issued a $395.00 target price on shares of Moderna in a research note on Friday, November 5th. Jefferies Financial Group dropped their target price on Moderna from $375.00 to $325.00 and set a “hold” rating for the company in a research note on Friday, November 5th. Finally, Wolfe Research began coverage on Moderna in a research report on Monday, November 8th. They set an “outperform” rating and a $304.00 price target for the company. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Moderna currently has a consensus rating of “Hold” and an average price target of $252.47.
The stock has a market cap of $59.44 billion, a PE ratio of 8.93, a P/E/G ratio of 0.25 and a beta of 1.22. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.35 and a quick ratio of 1.25. The business has a fifty day moving average of $254.17 and a 200 day moving average of $319.93.
Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 4th. The company reported $7.70 EPS for the quarter, missing analysts’ consensus estimates of $9.49 by ($1.79). The business had revenue of $4.97 billion during the quarter, compared to analysts’ expectations of $6.29 billion. Moderna had a net margin of 59.69% and a return on equity of 121.61%. The company’s revenue for the quarter was up 3065.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.59) EPS. On average, equities research analysts expect that Moderna, Inc. will post 26.32 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of MRNA. Corbenic Partners LLC purchased a new position in Moderna in the third quarter valued at about $25,000. Gradient Investments LLC raised its stake in Moderna by 2,000.0% during the fourth quarter. Gradient Investments LLC now owns 105 shares of the company’s stock valued at $27,000 after buying an additional 100 shares in the last quarter. Eagle Bay Advisors LLC raised its stake in Moderna by 200.0% during the fourth quarter. Eagle Bay Advisors LLC now owns 108 shares of the company’s stock valued at $27,000 after buying an additional 72 shares in the last quarter. Evermay Wealth Management LLC acquired a new stake in Moderna during the second quarter valued at approximately $28,000. Finally, Hall Laurie J Trustee acquired a new stake in Moderna during the fourth quarter valued at approximately $28,000. 59.11% of the stock is owned by hedge funds and other institutional investors.
About Moderna (NASDAQ:MRNA)
Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.